2型糖尿病患者使用利尿剂与下肢事件风险增加相关
基于SURDIAGENE前瞻性队列1459例2型糖尿病患者,中位随访7.1年,利尿剂使用者下肢事件发生率为1.80/100患者年,非使用者为1.00/100患者年(p<0.001)。多变量校正后利尿剂使用与下肢事件风险独立相关(HR 1.49,95%CI 1.01-2.19,p=0.04),主要驱动截肢风险(HR 2.01,95%CI 1.14-3.54,p=0.02)。
要点
- 利尿剂使用与2型糖尿病患者下肢事件风险独立相关,多变量校正HR 1.49。
- 风险主要来源于下肢截肢(HR 2.01),下肢血运重建无显著关联。
- 临床对使用利尿剂的2型糖尿病患者应关注下肢缺血与截肢风险。
核心结论
- 在2型糖尿病患者中,使用利尿剂与下肢事件风险显著增加相关,且主要体现为下肢截肢风险增加。
研究设计与样本
- SURDIAGENE为前瞻性观察性队列,纳入2002至2012年入组的2型糖尿病患者,随访至下肢事件发生、死亡或2015年12月31日。
- 共纳入1459例参与者,基线时670例使用利尿剂。
主要发现
- 中位随访7.1年,利尿剂使用者下肢事件发生率为1.80/100患者年,非使用者为1.00/100患者年(p<0.001)。
- 利尿剂使用者相比非使用者,下肢事件的未校正HR为2.08(95%CI 1.49-2.93),p<0.001。
- 多变量校正后HR为1.49(95%CI 1.01-2.19),p=0.04;以死亡为竞争风险时亚风险比为1.89(95%CI 1.35-2.64),p<0.001。
- 多变量校正模型中,下肢截肢与利尿剂使用相关(HR 2.01,95%CI 1.14-3.54,p=0.02),下肢血运重建无显著关联(HR 1.05,95%CI 0.67-1.64,p=0.84)。
临床怎么用
- 对使用利尿剂的2型糖尿病患者,应警惕下肢事件尤其截肢风险,加强下肢血管与足部评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS/HYPOTHESIS: Recently, safety data signalled an increased risk of amputations in people taking canagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor. If this side effect is due to drug-induced hypovolaemia, diuretics should also increase that risk. The aim of this study was to analyse the association between diuretic use and the risk of lower limb events (LLEs) in people with type 2 diabetes. METHODS: SURDIAGENE (SUivi Rénal, DIAbète de type 2 et GENEtique) is a prospective observational cohort that includes people with type 2 diabetes enrolled from 2002 to 2012 and followed-up until onset of LLE, death or 31 December 2015, whichever came first. Primary outcome was the first occurrence of LLE, a composite of lower limb amputation (LLA) and lower limb revascularisation (LLR). The rates of primary outcome were compared between participants taking and not taking diuretics at baseline in a Cox-adjusted model. RESULTS: At baseline, of the 1459 participants included, 670 were taking diuretics. In participants with and without diuretics, the mean ages were 67.1 and 62.9 years and 55.8% and 59.8% were men, respectively. During a median follow-up of 7.1 years, the incidence of LLE was 1.80 per 100 patient-years in diuretic users vs 1.00 in non-users (p < 0.001). The HR for LLE in users vs non-users was 2.08 (95% CI 1.49, 2.93), p < 0.001. This association remained significant in a multivariable-adjusted model (1.49 [1.01, 2.19]; p = 0.04) and similar after considering death as a competing risk (subhazard ratio 1.89 [1.35, 2.64]; p < 0.001). When separated, LLA but not LLR, was associated with the use of diuretics: 2.01 (1.14, 3.54), p = 0.02 and 1.05 (0.67, 1.64), p = 0.84, respectively, in the multivariable-adjusted model. CONCLUSIONS/INTERPRETATION: Among people with type 2 diabetes treated with diuretics, there was a significant increase in the risk of LLE, predominantly in the risk of LLA.
引用
- Potier L, Roussel R, Velho G, et al. Lower limb events in individuals with type 2 diabetes: evidence for an increased risk associated with diuretic use. Diabetologia. 2019. PMID: 30809716. doi:10.1007/s00125-019-4835-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。